Vyome Biosciences, a Delhi-based biopharmaceutical company focused on developing dermatology products, has closed a Series-B financing round worth $8 million (Rs 48 crore), led by Sabre Partners. Existing investors Kalaari Capital and Aarin Capital also participated.
Vyome is focused on the development of therapeutics for difficult-to-treat and refractory dermatology diseases. It has completed clinical research on two products and two lead compounds are in a pre-clinical stage of a US Food and Drug Administration programme.
Vyome says it is pioneering the development of a pipeline of molecules, including those for killing dandruff-causing fungus and new antibiotics that kill acne-causing bacteria, and has developed a robust global patent portfolio. It recently completed clinical studies on VB001 and VB2421 for mild-to-moderate dandruff.
Burmans buy into Experian
The Burman Family Office, of the promoters of Dabur Group, has made an equity investment in Experian Credit Information Company of India (ECICI), the Indian affiliate of Experian which operates in 39 countries, with revenue of $4.8 billion for the year ended March.
Langham Capital acted as an exclusive financial advisor to Burman Family Office, independent investment arm of the Burman family, also the controlling shareholders of fast-moving consumer goods company Dabur India. The details of the deal, equity stake bought and the value of the deal, were not disclosed.
ECICI provides credit information services to banks, non-banking financial companies and others.
foodpanda group raises $60 mn
foodpanda, with affiliated brands Hellofood and Delivery Club, has raised $60 million from a group of investors, including existing investors Falcon Edge Capital and Rocket Internet AG. In 2013, foodpanda secured $20 million funding from Phenomen Ventures and Investment AB Kinnevik, and $8 million from iMENA Holdings. Another $20 million was secured from a group of investors, including Phenomen Ventures, in February 2014.
Vyome is focused on the development of therapeutics for difficult-to-treat and refractory dermatology diseases. It has completed clinical research on two products and two lead compounds are in a pre-clinical stage of a US Food and Drug Administration programme.
Vyome says it is pioneering the development of a pipeline of molecules, including those for killing dandruff-causing fungus and new antibiotics that kill acne-causing bacteria, and has developed a robust global patent portfolio. It recently completed clinical studies on VB001 and VB2421 for mild-to-moderate dandruff.
Burmans buy into Experian
The Burman Family Office, of the promoters of Dabur Group, has made an equity investment in Experian Credit Information Company of India (ECICI), the Indian affiliate of Experian which operates in 39 countries, with revenue of $4.8 billion for the year ended March.
Langham Capital acted as an exclusive financial advisor to Burman Family Office, independent investment arm of the Burman family, also the controlling shareholders of fast-moving consumer goods company Dabur India. The details of the deal, equity stake bought and the value of the deal, were not disclosed.
ECICI provides credit information services to banks, non-banking financial companies and others.
foodpanda group raises $60 mn
foodpanda, with affiliated brands Hellofood and Delivery Club, has raised $60 million from a group of investors, including existing investors Falcon Edge Capital and Rocket Internet AG. In 2013, foodpanda secured $20 million funding from Phenomen Ventures and Investment AB Kinnevik, and $8 million from iMENA Holdings. Another $20 million was secured from a group of investors, including Phenomen Ventures, in February 2014.
If you have any information or announcements to share, please write to bsreporter@bsmail.in